Rituximab in combination with cyclosporine and steroid pulse therapy for childhood-onset multidrug-resistant nephrotic syndrome : a multicenter single-arm clinical trial (JSKDC11 trial)
© 2023. The Author(s)..
BACKGROUND: Only 80% of children with idiopathic nephrotic syndrome respond well to glucocorticoid therapy. Multidrug-resistant nephrotic syndrome (MRNS) is associated with a poor kidney prognosis. Several retrospective studies have identified rituximab as an effective treatment for MRNS; however, prospective studies are required to assess its efficacy and safety.
METHODS: We conducted a multicenter, non-blinded, single-arm trial to investigate the efficacy and safety of rituximab in patients with childhood-onset MRNS who were resistant to cyclosporine and more than three courses of steroid pulse therapy. The enrolled patients received four 375 mg/m2 doses of rituximab in combination with baseline cyclosporine and steroid pulse therapy. The primary endpoint was a > 50% reduction in the urinary protein/creatinine ratio from baseline on day 169. Complete and partial remissions were also evaluated.
RESULTS: Six patients with childhood-onset MRNS were enrolled. All patients were negative for pathogenic variants of podocyte-related genes. On day 169, five patients (83.3%) showed a > 50% reduction in the urinary protein/creatinine ratio, two patients showed partial remission, and two patients showed complete remission. No deaths occurred and severe adverse events occurred in two patients (infection in one patient and acute kidney injury in one patient). Three patients needed treatment for moderate-to-severe infection.
CONCLUSIONS: The study treatment effectively reduced the urinary protein/creatinine ratio in patients with childhood-onset MRNS. The adverse events in this study were within the expected range; however, attention should be paid to the occurrence of infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Clinical and experimental nephrology - 28(2024), 4 vom: 28. März, Seite 337-348 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nozu, Kandai [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 22.03.2024 Date Revised 23.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10157-023-02431-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36501673X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36501673X | ||
| 003 | DE-627 | ||
| 005 | 20240323234809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10157-023-02431-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1342.xml |
| 035 | |a (DE-627)NLM36501673X | ||
| 035 | |a (NLM)38010466 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nozu, Kandai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rituximab in combination with cyclosporine and steroid pulse therapy for childhood-onset multidrug-resistant nephrotic syndrome |b a multicenter single-arm clinical trial (JSKDC11 trial) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.03.2024 | ||
| 500 | |a Date Revised 23.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: Only 80% of children with idiopathic nephrotic syndrome respond well to glucocorticoid therapy. Multidrug-resistant nephrotic syndrome (MRNS) is associated with a poor kidney prognosis. Several retrospective studies have identified rituximab as an effective treatment for MRNS; however, prospective studies are required to assess its efficacy and safety | ||
| 520 | |a METHODS: We conducted a multicenter, non-blinded, single-arm trial to investigate the efficacy and safety of rituximab in patients with childhood-onset MRNS who were resistant to cyclosporine and more than three courses of steroid pulse therapy. The enrolled patients received four 375 mg/m2 doses of rituximab in combination with baseline cyclosporine and steroid pulse therapy. The primary endpoint was a > 50% reduction in the urinary protein/creatinine ratio from baseline on day 169. Complete and partial remissions were also evaluated | ||
| 520 | |a RESULTS: Six patients with childhood-onset MRNS were enrolled. All patients were negative for pathogenic variants of podocyte-related genes. On day 169, five patients (83.3%) showed a > 50% reduction in the urinary protein/creatinine ratio, two patients showed partial remission, and two patients showed complete remission. No deaths occurred and severe adverse events occurred in two patients (infection in one patient and acute kidney injury in one patient). Three patients needed treatment for moderate-to-severe infection | ||
| 520 | |a CONCLUSIONS: The study treatment effectively reduced the urinary protein/creatinine ratio in patients with childhood-onset MRNS. The adverse events in this study were within the expected range; however, attention should be paid to the occurrence of infections | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cyclosporine | |
| 650 | 4 | |a MRNS | |
| 650 | 4 | |a Methylprednisolone | |
| 650 | 4 | |a Rituximab | |
| 650 | 4 | |a SRNS | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Cyclosporine |2 NLM | |
| 650 | 7 | |a 83HN0GTJ6D |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Creatinine |2 NLM | |
| 650 | 7 | |a AYI8EX34EU |2 NLM | |
| 650 | 7 | |a Steroids |2 NLM | |
| 700 | 1 | |a Sako, Mayumi |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Seiji |e verfasserin |4 aut | |
| 700 | 1 | |a Kano, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Ohwada, Yoko |e verfasserin |4 aut | |
| 700 | 1 | |a Morohashi, Tamaki |e verfasserin |4 aut | |
| 700 | 1 | |a Hamada, Riku |e verfasserin |4 aut | |
| 700 | 1 | |a Ohtsuka, Yasufumi |e verfasserin |4 aut | |
| 700 | 1 | |a Oka, Masafumi |e verfasserin |4 aut | |
| 700 | 1 | |a Kamei, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Inaba, Aya |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Shuichi |e verfasserin |4 aut | |
| 700 | 1 | |a Sakai, Tomoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kaito, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Shima, Yuko |e verfasserin |4 aut | |
| 700 | 1 | |a Ishikura, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Hidefumi |e verfasserin |4 aut | |
| 700 | 1 | |a Nakanishi, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Horinouchi, Tomoko |e verfasserin |4 aut | |
| 700 | 1 | |a Konishi, Akihide |e verfasserin |4 aut | |
| 700 | 1 | |a Omori, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Iijima, Kazumoto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental nephrology |d 1998 |g 28(2024), 4 vom: 28. März, Seite 337-348 |w (DE-627)NLM096492473 |x 1437-7799 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2024 |g number:4 |g day:28 |g month:03 |g pages:337-348 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10157-023-02431-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2024 |e 4 |b 28 |c 03 |h 337-348 | ||